Skip to main content

Table 1 Primary and secondary outcomes of the study

From: Antiplatelet therapy for the prevention of atherosclerosis in chronic kidney disease (ALTAS-CKD) patients: study protocol for a randomized clinical trial

Outcome Metric Time point
Atherosclerosis Occurrence rate of atherosclerosis 36 months
 The combined cardiovascular events Incidence 36 months
 All-cause mortality Incidence 36 months
 eGFR decreased by 50% the proportion of eGFR decreased by 50% 36 months
 Safety outcomes Numbers 36 months